**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 58666

**Manuscript Type:** REVIEW

**Donor-specific cell-free DNA as a biomarker in liver transplantation: A review**

McClure T *et al*. Donor-specific cell-free DNA in LT

Tess McClure, Su Kah Goh, Daniel Cox, Vijayaragavan Muralidharan, Alexander Dobrovic, Adam G Testro

**Tess McClure, Adam G Testro,** Liver Transplant Unit, Austin Health, Heidelberg 3084, VIC, Australia

**Su Kah Goh, Daniel Cox, Vijayaragavan Muralidharan,** Department of Surgery, Austin Health, Heidelberg 3084, VIC, Australia

**Alexander Dobrovic,** Department of Surgery, The University of Melbourne, Heidelberg 3084, VIC, Australia

**Author contributions:** McClure T and Goh SK wrote the paper; Cox D, Muralidharan V, Dobrovic A and Testro AG edited the manuscript; all authors approved of the final version agree to be accountable for its contents.

**Supported by** The University of Melbourne, Parkville 3000, VIC, Australia

**Corresponding author: Tess McClure, FRACP, MBBS, Gastroenterologist and Hepatologist, PhD candidate,** Liver Transplant Unit, Austin Health, 145 Studley Rd, Heidelberg 3084, VIC, Australia. tess.mcclure@austin.org.au

**Received:** August 2, 2020

**Revised:** October 9, 2020

**Accepted:** October 30, 2020

**Published online:** November 28, 2020

**Abstract**

Due to advances in modern medicine, liver transplantation has revolutionised the prognosis of many previously incurable liver diseases. This progress has largely been due to advances in immunosuppressant therapy. However, despite the judicious use of immunosuppression, many liver transplant recipients still experience complications such as rejection, which necessitates diagnosis *via* invasive liver biopsy. There is a clear need for novel, minimally-invasive tests to optimise immunosuppression and improve patient outcomes. An emerging biomarker in this ‘‘precision medicine’‘ liver transplantation field is that of donor-specific cell free DNA. In this review, we detail the background and methods of detecting this biomarker, examine its utility in liver transplantation and discuss future research directions that may be most impactful.

**Key Words:** Biomarkers; Precision medicine; Donor-specific cell-free DNA; Liver transplantation; Rejection; Review

**Citation:** McClure T, Goh SK, Cox D, Muralidharan V, Dobrovic A, Testro AG. Donor-specific cell-free DNA as a biomarker in liver transplantation: A review. *World J Transplant* 2020; 10(11): 307-319

**URL:** https://www.wjgnet.com/2220-3230/full/v10/i11/307.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v10.i11.307

**Core Tip:** Donor-specific cell-free DNA is a biomarker with promising clinical utility in liver transplantation. It demonstrates stereotypic dynamics in states of graft health, and is an early and accurate marker of acute rejection. This has been demonstrated in other solid-organ transplantations, where certain assays have progressed to commer-cialisation. Further studies examining donor-specific cell free DNA in liver transplantation, such as a randomised controlled trial or in combination with other assays, will assist with its translation into clinical practice. Ultimately, this emerging biomarker will need to be used in an integrated manner by experienced clinicians so as to improve patient outcomes.

**INTRODUCTION**

Liver transplantation (LT) is a crucial treatment option for many patients with advanced liver disease. Since it was first performed in 1963[1], LT has evolved so significantly that it has revolutionised the prognosis of previously incurable conditions. Today, recipients have overall survival rates of 96% at one year, 71% at 10 years and–remarkably–52% at 20 years post-LT[2]. In line with these excellent outcomes, the number of LTs performed each year continues to rise. In 2017, more than 32000 LTs occurred worldwide–representing 23.5% of the total organs transplanted and a 16.5% increase in LTs since 2015[3].

Long-term, the success of a LT depends on a fine balance: Adequately suppressing the immune system to avoid organ rejection, whilst maintaining it at a level that prevents complications and minimises side effects. Notably, the level of immunosuppression required post-LT can vary substantially between recipients. Whilst some patients are highly prone to rejection[4], others can successfully wean off immunosuppression entirely–achieving ‘‘operational tolerance’‘[5]. Despite the judicious use of immunosuppression, up to 27% of LT recipients still develop an episode of acute rejection and 68% encounter infective complications[6-8]. LT recipients also experience increased rates of malignancy, renal impairment and metabolic syndrome compared to the general population[9-11]. These issues can threaten graft and patient survival, impair quality of life and prove costly to manage[12-14].

Currently, the standard of care post-LT involves commencing recipients on empiric doses of immunosuppression, which are adjusted according to changes in liver function tests (LFTs), serum drug levels or the onset of an adverse clinical event. Whist LFTs are an extremely sensitive test for detecting organ injury, they are poorly specific for LT complications[15]. Moreover, no clear LFT thresholds exist that are diagnostic of rejection or reflective of its severity[16]. Similarly, there are no defined therapeutic ranges for serum calcineurin inhibitor (CNI) levels[17], as these have been shown to poorly correlate with clinical effects–particularly in LT[18]. Therefore, these tests often lead to a series of radiological and endoscopic investigations, that culminate in a liver biopsy to diagnose rejection. Not only is this process time-consuming and resource-heavy, but liver biopsies are inherently subjective and invasive[19]. Approximately 1 in 100 result in major complications and 2 in 1000 lead to patient death[20,21].

Clearly, innovative tools are needed to optimise immunosuppression and improve patient outcomes post-LT. Ideally, such tests should be both sensitive and specific for LT complications, as well as minimally invasive and cost-effective[22]. These tests also need to be easily accessible and rapidly performed, as changes in a LT recipient’s condition can occur quickly[23], and clinicians need to make prompt decisions in real time. To date, there has been considerable research into identifying biological markers that could enable clinicians to more precisely tailor immunosuppression regimens to individual patients[24-26]. One such emerging biomarker in this field of ‘‘precision medicine’‘ is that of circulating free DNA from the donor graft (*i.e.* ‘‘donor-specific cell-free DNA’‘). In this review, we detail the background and methods of detecting this biomarker, examine its utility in LT, and discuss future research directions that may be most impactful.

**DONOR-SPECIFIC CELL-FREE DNA**

***Background***

Unencapsulated or ‘‘cell-free’‘ DNA was first discovered in human plasma by Mandel and Metais in 1948[27]. Following a resurgence of interest into its clinical potential in the 1990s[28], the scientific community has since learnt much about the biology of cell-free DNA. The majority originates from haematopoetic cells such as leukocytes[29,30], and is released into the circulation during apoptosis and necrosis[31-33]. These fragments of DNA are then rapidly cleared from plasma by the liver, spleen and kidneys[34,35]. As a result, cell-free DNA has a short half-life of approximately 1.5 h[36,37]–rendering it a ‘‘real-time’‘ marker of cellular injury. Subsequently, scientists identified that lower levels of this circulating free DNA were also being released during normal physiological turnover[38-40].

Given these characteristics, cell-free DNA has emerged as a useful biomarker in multiple clinical settings. This was particularly notable in those where a genetic difference could be exploited, such as oncology, obstetrics or solid-organ transplantation. In cancer patients, researchers isolated circulating free DNA characterised by mutations specific to particular malignancies[41-43]. This gave rise to the notion of a ‘‘liquid biopsy’‘ for diagnostic and management purposes[44-47]. Similarly, in the plasma of pregnant women, researchers detected fragments of DNA unique to the foetus[28], and subsequently analysed these for genetic conditions[48]. Today, ‘‘non-invasive pre-natal testing’‘ has replaced the need for chorionic villus sampling with a simple blood test[49], which is commercially available throughout the world[50]. In solid-organ transplantation, genetic differences become fundamentally intertwined. With the exception of an identical twin donor-recipient pair, this procedure places a unique genome within the recipient–theoretically creating the ideal environment for detecting circulating free donor DNA *via* minimally-invasive blood sampling. Moreover, this biomarker could plausibly reflect graft integrity at low levels, and cellular death when elevated. A particular focus has emerged regarding the dynamics of this DNA during rejection, given it is this element of solid-organ transplantation that currently necessitates invasive biopsies. This is particularly the case in LT, where routine biopsies are considered controversial–and often only performed if clinically indicated[51,52]. Clearly, a liquid biopsy could be revolutionary in this setting.

***Methods of detection***

In order to critically appraise studies examining the clinically utility of donor-specific cell-free DNA in LT, it is important to understand the scientific advancements that have enhanced its detection.

***Y-chromosome specific sequences***

The first group to detect circulating free donor DNA in transplant recipient plasma were Lo *et al*[53] in 1998. In their landmark study, they isolated fragments of donor DNA in the plasma of 36 liver or kidney transplant recipients–including six females who had received livers from male donors. In this subset of participants, the authors isolated genetic sequences unique to the Y-chromosome, which they amplified using polymerase chain reaction (PCR) and visualised using gel electrophoresis. In so doing, they provided ground-breaking data proving the concept of donor-specific cell-free DNA, depicted in Figure 1. However, this methodology was limited to male-to-female engraftments only–just as a subsequent Rhesus (Rh) gene quantitative PCR (qPCR) assay was restricted to positive-to-negative transplantations[54]. As such, a focus on identifying other genetic targets that differed more broadly between individuals subsequently emerged.

***Next generation sequencing***

The following decade, the advent of next generation sequencing (NGS) completely revolutionised gene discovery. By enabling massive genetic throughputs[55], multiple genetic loci that were highly heterogeneous within the population could now be identified. The most common of these were ‘‘single nucleotide polymorphisms’‘ (SNPs)–where DNA sequences differed by one adenine, thymine, guanine or cytosine molecule between individuals[56]. By using NGS to analyse multiple SNPs, researchers could now detect genetic sequences likely to differ between the vast majority of donor-recipient pairs. The first group to achieve this were Snyder *et al*[57] in 2011, who analysed blood samples from heart transplant donors and recipients, and detected circulating free donor DNA using a genome-wide SNP assay[57]. Since then, three other groups have published more targeted NGS methodology in this field[58-60], two of which circumvented this need for baseline donor blood sampling by using computational techniques[59,60]. However, in clinical practice, NGS assays have several key limitations. Not only are they highly complex and expensive, but they can take up to seven days to process[57]–rendering them potentially futile as a real-time transplantation biomarker.

***Droplet-digital polymerase chain reaction***

Given this, an interest in developing more accessible, affordable and rapid assays arose. This coincided with the commercial availability of droplet digital PCR (ddPCR), which had a six hour turnaround time, and could more precisely quantify DNA than previous qPCR techniques[61]. Researchers began designing new ddPCR probes and primers to detect donor-specific sequences. Y-chromosome and SNP targets were revisited, but new sites included regions of the human leukocyte antigen (HLA) gene and ‘‘deletion insertion polymorphisms’‘ (DIPs). At a population level, HLA genes are characterised by high levels of heterogeneity[62]. However, as donor-recipient pairs are often HLA ‘‘matched’‘[63], this target is potentially problematic in transplantation. DIPs, conversely, remain a promising option–as these are regions of the genome characterised by the absence or presence of certain nucleotides, leading to common allelic differences between individuals[64]. Ultimately, understanding these methodologies highlights the relative complexity of genetic tests, compared to more standard biochemistry such as LFTs[65]. Accordingly, each assay for circulating free donor DNA requires validation, in order to establish its utility in the clinical setting.

**STUDIES IN LIVER TRANSPLANTATION**

***Publications to date***

A total of 12 publications have studied donor-specific cell-free DNA in LT, as summarised in Table 1. These studies differ in their size (*n* = 1-115), design and assay methodologies. However, they all demonstrate that this biomarker shows promise in monitoring graft health and detecting injury–especially when caused by acute rejection.

Fifteen years after Lo *et al*[53] first demonstrated the presence of Y-specific donor DNA fragments in LT recipient plasma, Beck *et* *al*[66] went on to establish three additional key findings. In their 2013 study, they used probe-based ddPCR to scrutinise a panel of 40 SNPs and detect donor-specific sequences in 10 newly transplanted and seven stable LT recipients. These fragments of donor DNA were then quantified in terms of relative abundance and expressed as a percentage of total cell-free DNA. Firstly, Beck *et al*[66] observed high levels of circulating free donor DNA post-engraftment (approximately 90%), which fell exponentially and stabilised within 10 d in recipients without complications. Secondly, this DNA was elevated (> 60%) in two newly transplanted patients with biopsy-proven acute rejection (BPAR), yet not in another with obstructive cholestasis. Notably, this DNA began to increase several days prior to LFTs in those cases with rejection. Thirdly, the authors identified a ‘‘healthy’‘ threshold of donor-specific cell-free DNA of < 10% in the stable LT recipients. Additional benefits of this assay included its same-day turnaround and lack of a need for donor blood sampling. However, its limitations included the use of PCR preamplification and post-PCR handling, which can introduce several forms of bias and pose a high contamination risk, respectively[67].

The next year, Macher *et al*[68]published a longitudinal study using qPCR to detect Y-specific DNA fragments in 10 gender-mismatched LT recipients*.* As with Beck *et al*[66], the authors also found that this circulating free donor DNA was elevated immediately post-LT, then rapidly decreased in recipients without complications and remained stable[68]. Macher *et al*[68]also identified a threshold reflective of organ health–however as their assay was one of absolute quantification, this was expressed as 150 ng/mL. The authorsmade the novel observation that these fragments of donor DNA were also elevated in recipients who experienced cholangitis and vascular complications. Unfortunately, this study proved too small to examine the dynamics of this DNA in acute rejection, as no patients experienced this endpoint. As such, Macher *et al*[54]subsequently published an additional study in 2016. This time, they measured circulating free donor DNA by using qPCR to detect Rh-positive sequences in 17 Rh-mismatched LT recipients. Here, in the patients who experienced BPAR, levels of donor-specific cell-free DNA were found to rise compared to those without complications. However, as these two qPCR assays targeted restrictive genetic differences only, they intrinsically had limited clinical utility.

Between 2014 and 2017, the Beck group published three additional studies using their more expansive SNP methodology[69-71]. The first of these was a case study, which described a LT recipient of a marginal graft, who had experienced multiple complications post-operatively–and retrospectively undergone donor-specific cell-free DNA analysis[69]. Kanzow *et al*[69]demonstrated that levels rapidly became elevated in the following settings: BPAR, traumatic liver haematoma and cytomegalovirus infection. They also made the pioneering observation that circulating free donor DNA subsequently fell post successful treatment of each complication. The authors concluded that this biomarker was useful for monitoring organ health.

Next, Oellerich *et al*[70] prospectively measured circulating free donor DNA and CNI levels in 10 receipts during the first month post-LT. They aimed to identify the minimum trough tacrolimus concentration that was associated with graft integrity. Using the pre-established healthy threshold of < 10%, the authors observed significant segregation and determined the lower limit of the therapeutic tacrolimus range to be 8 ug/L. Although larger studies with longer follow up were still needed, Oellerich *et al*[70] postulated the assay could be useful in monitoring for graft injury in LT recipients whose immunosuppression was being weaned.

This unmet need was addressed by the third study, published by Schütz *et al*[71] In their multicentre prospective trial, donor-specific cell-free DNA was measured in 115 LT recipients at seven timepoints during the first year post-LT, plus whenever rejection was suspected. The stereotypic exponential fall of this DNA was seen in 88 stable recipients, who had a median level of 3.3%. In 17 recipients with BPAR, median levels were elevated at 29.6%. Moreover, this circulating free donor DNA was found to be an accurate and early marker of BPAR–with a superior area under the receiver operating characteristic curve (AUC) of 0.97 compared to LFTs (0.83-0.96), and levels increasing up to two weeks prior to diagnosis on liver biopsy. In patients with infective complications, median donor-specific cell-free DNA was slightly higher than in stable recipients, but lower than in BPAR (5.3%-5.7%) – similar to patterns seen by other authors[68,69]. In patients with cholestasis alone, levels remained < 10%[71]. On multivariate logistic regression, Schütz *et al*[71] found that this biomarker provided independent information regarding graft integrity.

Whilst the benefits of the Beck *et al*[72] assay they utilised prevailed, there were several limitations to this study[71]. These were highlighted by two cases, where patients had BPAR, but circulating free donor DNA levels remained < 10%. In the first patient, who had a marked leukocytosis, Schütz *et al*[71]acknowledged that this factor may have ‘‘masked’‘ the percentage of cell-free DNA from the donor present in recipient plasma, due to an increase in the denominator of total cell-free DNA. Indeed, expressing circulating free donor DNA in terms of relative abundance renders it innately susceptible to this form of error–including in other circumstances where cell-free DNA increases such as infection[73], obesity[74] and exercise[75]. In the second patient with BPAR but circulating free donor DNA below the ‘‘healthy’‘ threshold, the authors attributed this to the fact that the rejection was only mild histologically, with a rejection activity index (RAI) of 1/9, and did not require treatment[71]. This case demonstrates the limited clinical utility of BPAR as an endpoint–compared to treated BPAR (tBPAR) of RAI ≥ 3, which is now widely utilised in clinical trials[76,77].

These limitations, however, were not present in the Goh *et al*[78]publication from 2019. This group originally validated their probe-free ddPCR assay in 2017, when they successfully targeted a panel of nine DIPs and achieved absolute quantification of circulating free donor DNA in three LT recipients[79]. Two years later, theyused this technique to examine 40 recipients divided into two cohorts[78]: Longitudinal (*n* = 20), who had donor-specific cell-free DNA measured at five timepoints during the first six weeks post-LT; and cross-sectional, who were either undergoing a liver biopsy at least one-month post-LT (*n* = 16), or stable and at least one-year post-LT (*n* = 4). The authors demonstrated findings in keeping with the aforementioned literature. In the longitudinal group, levels of circulating free donor DNA fell exponentially and stabilised in the 14 recipients without complications. Elevated levels of this DNA were observed in three recipients with tBPAR, but not in three with cholestasis alone. In the cross-sectional cohort, elevated levels of this DNA accurately identified six patients with tBPAR, with an AUC of 0.97 that was again superior to LFTs. A healthy threshold of < 898 copies/mL was identified in the 14 cross-sectional patients without rejection and found to be reliable in the longitudinal cohort from day 14 post-LT onward. By using primer sets to hybridize across allelic breakpoints, Goh *et al*[78] had also eliminated the need for costly florescent probes. However, the assay called for a donor blood sample for optimal processing and the study was ultimately underpowered.

Most recently, Ng *et al*[80-82] pioneered the measurement of circulating free donor DNA in live donor LT (LDLT). These authors utilised different assays to detect the relative abundance of this DNA in paediatric recipients from day 0-60 post-LDLT. First, NGS was used to detect Y-specific sequences in two gender-mismatched LDLTs96. Next, a qPCR SNP assay was examined in two additional LDLT recipients97. In both publications, Ng *et al*[82] found that circulating free donor DNA exponentially fell and stabilised at < 0.1, as seen with the Beck *et al*[66] group. Finally, the initial NGS Y-specific assay was used in 7 gender-mismatched LDLTs to detect circulating free donor DNA, which was then profiled according to its fragment size[82]. Here, the authors made the innovative observation that donor DNA fragments were ‘‘short’‘ (105-145 bp), compared to the ‘‘long’‘ fragments of recipient DNA (> 160-170 bp). NGS and automated electrophoresis was then used to detect these short donor DNA fragments in four gender-matched LDLT recipients. The authors also noted that the ratio of short to long (S/L) fragments correlated with the circulating free donor DNA levels–and identified a healthy S/L fragment threshold of < 0.6. Interestingly, in the oncology and obstetric research settings, the fragments of DNA from tumour cells or from the foetus are also shorter (*i.e.* than those from non-malignant or maternal cells respectively) but the mechanism behind this is unclear[83,84]. Certainly, this Ng *et al*[80-82] fragment size-based assay was quicker and less restrictive than targeting the Y-chromosome. However, its methodology was still slower (24 h) and more expensive than PCR. Furthermore, these three studies were limited by their small sample size of uneventful LDLTs[80-82]–precluding insights into the dynamics of their assays during complications.

**DISCUSSION**

In summary, these studies show that donor-specific cell-free DNA is a biomarker with promising clinical utility in LT. It consistently demonstrates stereotypic dynamics in states of graft health[54,66,68,71,78]. As such, it could be used to rule out organ injury as part of a diagnostic workup post-LT. In the setting of acute rejection, circulating free donor DNA repeatedly outperforms LFTs in terms of both its discriminatory and timely detection of this LT complication[71]. Given this, it could be used to prompt early adjustments to therapy if rising in the setting of an immunosuppression wean–potentially preventing an episode of tBPAR. It could also be used to avoid a liver biopsy when present at low levels, enabling clinicians to observe recipients or investigate less invasively knowing tBPAR is highly unlikely. Ultimately, further studies are required to fully establish the potential of donor-specific cell-free DNA as a ‘‘liquid biopsy’‘ in LT. In particular, a focus on identifying thresholds diagnostic of acute rejection, or reflective of its effective treatment, would be of high clinical value.

Reflecting on the biology underlying these results also yields further insights. Firstly, the researchers who discovered that circulating free donor DNA was more sensitive and specific for acute rejection than LFTs have postulated as to why this is the case[71,78]. Both Schütz *et al*[71] and Goh *et al*[78] concluded that, compared to LFTs, elevated levels of this novel biomarker reflect a relatively simple process–that of donor organ cellular death, releasing DNA into the recipient circulation. Conversely, bilirubin and the liver enzymes can rise due to a number of complex pathways. Secondly, other researchers have shown that levels of circulating free donor DNA also rise in infective and vascular complications post-LT[68,69,71]. Whilst these are also potential causes of graft cell death, other studies have indicated that inflammatory states might affect cell-free DNA levels[85]. Therefore, as a potential biomarker, these donor-specific assays need to be carefully interpreted by expert clinicians within the clinical context. Finally, in contrast to LFTs, circulating free donor DNA levels were noted in several studies to remain stable in the setting of cholestasis alone[66,71,78]. Whilst the reasons for this remain unclear, potential explanations could include the different vasculature of the biliary tree compared to hepatocytes, or its drainage system into the duodenum.

Additional issues that have been addressed include the impact of ‘‘blood microchimerism’‘ from donor leukocytes, or of blood transfusions from other/pooled donors. In their landmark study, Lo *et al*[53] did not detect any haematopoietic donor cells in the recipients’ circulation. Subsequently, Schütz *et al*[71] analysed a subset of 12 patients, and found donor leukocytes were either absent or barely present (0%-0.068%). Both authors therefore concluded that blood microchimerism could be excluded as a confounding source of circulating free donor DNA[53,71]. Conversely, an additional case report by Goh *et al*[86] found that their assay was affected by blood transfusions. In this LT recipient, with no other evidence of graft injury, donor-specific cell-free DNA rapidly rose and fell post receiving fresh frozen plasma (FFP). As such, the authors suspected the FFP had temporarily confounded their results. However, given the short half-life of unencapsulated DNA, this could potentially be controlled for by performing assays for circulating free donor DNA several hours post such transfusions.

Ultimately, these LT studies represent just one aspect of the broader donor-specific cell-free DNA literature. In a recent systematic review, Knight *et al*[25] identified 47 studies examining this biomarker in solid-organ transplantation (census date June 2018). Most were in kidney (38.3%) or heart (23.4%) transplant recipients, and a smaller number were from the lung (10.6%) and kidney-pancreas (2.1%) setting. As with the LT literature, these studies varied in their design, size (*n* = 1-384) and assay methodologies. In five studies, the same assay was validated across multiple organs. In their narrative analysis, the reviewersfound comparable results across multiple organs–with a few specific nuances. In all 21 studies that examined newly transplanted patients, circulating free donor DNA fell and stabilised by day 10. However, liver and lung recipients had higher baseline mean levels (2%-5%) than kidney and heart recipients (0.06%-1.2%)–potentially due to their larger graft size. Of the 41 studies that examined this biomarker in acute rejection, the vast majority observed levels to increase (97.5%), yet less than half reported diagnostic accuracy data (46.3%). Interestingly, of all organs studied, circulating free donor DNA rose to higher thresholds and with greater accuracy for BPAR in LT. Whilst no studies identified thresholds diagnostic of BPAR, several noted that levels returned to baseline post successful treatment. Overall, Knight *et al*[25] concluded that donor-specific cell-free DNA was a valid biomarker in all organ types.

Since then, the literature has continued to rapidly evolve. At the time of writing, more than 25 additional studies examining circulating free donor DNA had been published–including several from large cohorts of kidney (*n* = 107-189)[87,88], heart (*n* = 241-773)[89,90] and lung (*n* = 106)[91] transplant recipients. Additional developments have included the publication of new guidelines regarding optimal laboratory processing of cell-free DNA[92]. There has also been an emerging interest in other cell-free genetic targets, such as hepatocyte-specific methylation markers[93,94], and mitochondria-derived DNA (mDNA)[95,96]. Finally, some of these studies have led to the commercialisation of particular dsfDNA assays. AlloSure® and AlloMap® (CareDx, Inc., Brisbane CA) have been validated in large cohorts of kidney and heart transplants recipients respectively[89,97-99]. Prospera® (Natera, Inc., San Carlos CA) has also been validated in a renal transplant study[100]. Yet, as these three assays are all NGS-based, their routine use in clinical practice remains problematic. More recently, myTAIHEART® (TAI Diagnostics, Inc., Wauwatosa WI), which targets SNPs with qPCR to quantify circulating free donor DNA in relative abundance, was validated in heart transplant recipients[89,90]. However, as baseline thresholds and diagnostic accuracy of these assays can differ across organ types, they require further validation prior to their potential use in LT.

**CONCLUSION**

Given the rising number of LT recipients who require long-term monitoring[2,3], further donor-specific cell-free DNA research in this field could be of high clinical impact. Currently, there are two large prospective trials underway further examining AlloSure® in kidney transplantation (ClinicalTrials.gov Identifier: NCT03326076), and its use in conjunction with AlloMap® in heart transplantation (ClinicalTrials.gov Identifier: NCT03695601). Clearly, the commercialisation and larger scale analysis of circulating free donor DNA in LT is also required. Following this, next steps should include a randomised controlled trial (RCT) comparing standard of care post-LT to precision medicine additionally guided by changes in donor-specific cell-free DNA levels. Ideally, this RCT should also include a comparative cost analysis of these two models of care. Lastly, LT studies combining this biomarker with other novel tests would be particularly impactful–such as those quantifying immune function[77], or machine learning algorithms[26]. Ultimately, the use of innovative tools in an integrated manner could enable clinicians to continue the legacy of exceptional progress and further improve patient outcomes post-LT.

**ACKNOWLEDGEMENTS**

Thank you to Simon Cockroft for creating the image used in Figure 1, and to Dr Bruce McClure for his diligent proofreading.

**REFERENCES**

1 **Starzl TE**, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, Schade RR, Shaw BW Jr, Hakala TR, Rosenthal JT, Porter KA. Evolution of liver transplantation. *Hepatology* 1982; **2**: 614-636 [PMID: 6749635 DOI: 10.1002/hep.1840020516]

2 **Adam R**, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A; All contributing centers (www.eltr.org); European Liver and Intestine Transplant Association (ELITA). Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012; **57**: 675-688 [PMID: 22609307 DOI: 10.1016/j.jhep.2012.04.015]

3 **Global Observatory on Donation and Transplantation**. World Health Organization (WHO) and Organización Nacional de Trasplantes (ONT), 2019. Available from: https://www.who.int/transplantation/knowledgebase/en/

4 **Dogan N**, Hüsing-Kabar A, Schmidt HH, Cicinnati VR, Beckebaum S, Kabar I. Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure. *J Int Med Res* 2018; **46**: 3979-3990 [PMID: 29996675 DOI: 10.1177/0300060518785543]

5 **Lerut J**, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. *Am J Transplant* 2006; **6**: 1774-1780 [PMID: 16889539 DOI: 10.1111/j.1600-6143.2006.01396.x]

6 **Winston DJ**, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. *Clin Infect Dis* 1995; **21**: 1077-89; quiz 1090-1 [PMID: 8589125 DOI: 10.1093/clinids/21.5.1077]

7 **Patel R**, Paya CV. Infections in solid-organ transplant recipients. *Clin Microbiol Rev* 1997; **10**: 86-124 [PMID: 8993860 DOI: 10.1128/CMR.10.1.86-124.1997]

8 **Levitsky J**, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, Lok AS, Levy G, Kulik L, Abecassis M, Shaked A. Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients. *Clin Gastroenterol Hepatol* 2017; **15**: 584-593.e2 [PMID: 27567694 DOI: 10.1016/j.cgh.2016.07.035]

9 **Ojo AO**, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003; **349**: 931-940 [PMID: 12954741 DOI: 10.1056/NEJMoa021744]

10 **Chak E**, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. *Liver Int* 2010; **30**: 1247-1258 [PMID: 20602682 DOI: 10.1111/j.1478-3231.2010.02303.x]

11 **Laish I**, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. *Liver Transpl* 2011; **17**: 15-22 [PMID: 21254340 DOI: 10.1002/lt.22198]

12**30th ANZLITR Report**,Australia and New Zealand Liver and Intestinal Transplant Registry, 2018. Available from: https://www.anzlitr.org/wp-content/uploads/Reports/30thReport.pdf

13 **Desai R**, Jamieson NV, Gimson AE, Watson CJ, Gibbs P, Bradley JA, Praseedom RK. Quality of life up to 30 years following liver transplantation. *Liver Transpl* 2008; **14**: 1473-1479 [PMID: 18825684 DOI: 10.1002/lt.21561]

14 **Ammori JB**, Pelletier SJ, Lynch R, Cohn J, Ads Y, Campbell DA, Englesbe MJ. Incremental costs of post-liver transplantation complications. *J Am Coll Surg* 2008; **206**: 89-95 [PMID: 18155573 DOI: 10.1016/j.jamcollsurg.2007.06.292]

15 **Hickman PE**, Potter JM, Pesce AJ. Clinical chemistry and post-liver-transplant monitoring. *Clin Chem* 1997; **43**: 1546-1554 [PMID: 9265907 DOI: [10.1093/clinchem/43.8.1546](https://doi.org/10.1093/clinchem/43.8.1546)]

16 **Rodríguez-Perálvarez M**, Germani G, Tsochatzis E, Rolando N, Luong TV, Dhillon AP, Thorburn D, O'Beirne J, Patch D, Burroughs AK. Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. *Transpl Int* 2012; **25**: 555-563 [PMID: 22420754 DOI: 10.1111/j.1432-2277.2012.01457.x]

17 Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA. US Department of Health and Human Services, Food and Drug Admisitration, Centre for Devisions and Radiological Health, 2002. Available from: https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/cyclosporine-and-tacrolimus-assays-class-ii-special-controls-guidance-document-industry-and-fda

18 **Kershner RP**, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. *Transplantation* 1996; **62**: 920-926 [PMID: 8878385 DOI: 10.1097/00007890-199610150-00009]

19 **Thung SN**, Gerber MA. Histological features of liver allograft rejection: do you see what I see? *Hepatology* 1991; **14**: 949-951 [PMID: 1937399 DOI: 10.1002/hep.1840140530]

20 **Boyum JH**, Atwell TD, Schmit GD, Poterucha JJ, Schleck CD, Harmsen WS, Kamath PS. Incidence and Risk Factors for Adverse Events Related to Image-Guided Liver Biopsy. *Mayo Clin Proc* 2016; **91**: 329-335 [PMID: 26837481 DOI: 10.1016/j.mayocp.2015.11.015]

21 **West J**, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. *Gastroenterology* 2010; **139**: 1230-1237 [PMID: 20547160 DOI: 10.1053/j.gastro.2010.06.015]

22 **Maxim LD**, Niebo R, Utell MJ. Screening tests: a review with examples. *Inhal Toxicol* 2014; **26**: 811-828 [PMID: 25264934 DOI: 10.3109/08958378.2014.955932]

23 **Feltracco P**, Barbieri S, Galligioni H, Michieletto E, Carollo C, Ori C. Intensive care management of liver transplanted patients. *World J Hepatol* 2011; **3**: 61-71 [PMID: 21487537 DOI: 10.4254/wjh.v3.i3.61]

24 **Sood S**, Testro AG. Immune monitoring post liver transplant. *World J Transplant* 2014; **4**: 30-39 [PMID: 24669365 DOI: 10.5500/wjt.v4.i1.30]

25 **Knight SR**, Thorne A, Lo Faro ML. Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review. *Transplantation* 2019; **103**: 273-283 [PMID: 30308576 DOI: 10.1097/TP.0000000000002482]

26 **Fu S**, Zarrinpar A. Recent advances in precision medicine for individualized immunosuppression. *Curr Opin Organ Transplant* 2020; **25**: 420-425 [PMID: 32520785 DOI: 10.1097/MOT.0000000000000771]

27 **Mandel P**, Metais P. Nuclear Acids In Human Blood Plasma. *C R Seances Soc Biol Fil* 1948; **142**: 241-243 [PMID: 18875018]

28 **Lo YM**, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. *Lancet* 1997; **350**: 485-487 [PMID: 9274585 DOI: 10.1016/S0140-6736(97)02174-0]

29 **Lui YY**, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. *Clin Chem* 2002; **48**: 421-427 [PMID: 11861434 DOI: [10.1093/clinchem/48.3.421](https://doi.org/10.1093/clinchem/48.3.421)]

30 **Lui YY**, Woo KS, Wang AY, Yeung CK, Li PK, Chau E, Ruygrok P, Lo YM. Origin of plasma cell-free DNA after solid organ transplantation. *Clin Chem* 2003; **49**: 495-496 [PMID: 12600963 DOI: 10.1373/49.3.495]

31 **Giacona MB**, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. *Pancreas* 1998; **17**: 89-97 [PMID: 9667526 DOI: 10.1097/00006676-199807000-00012]

32 **Stroun M**, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. *Clin Chim Acta* 2001; **313**: 139-142 [PMID: 11694251 DOI: 10.1016/s0009-8981(01)00665-9]

33 **Fan HC**, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. *Clin Chem* 2010; **56**: 1279-1286 [PMID: 20558635 DOI: 10.1373/clinchem.2010.144188]

34 **Yu SC**, Lee SW, Jiang P, Leung TY, Chan KC, Chiu RW, Lo YM. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. *Clin Chem* 2013; **59**: 1228-1237 [PMID: 23603797 DOI: 10.1373/clinchem.2013.203679]

35 **Butler TM**, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. *Curr Opin Genet Dev* 2017; **42**: 14-21 [PMID: 28126649 DOI: 10.1016/j.gde.2016.12.003]

36 **Gauthier VJ**, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. *J Immunol* 1996; **156**: 1151-1156 [PMID: 8557992]

37 **Celec P**, Vlková B, Lauková L, Bábíčková J, Boor P. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases. *Expert Rev Mol Med* 2018; **20**: e1 [PMID: 29343314 DOI: 10.1017/erm.2017.12]

38 **Anker P**, Stroun M, Maurice PA. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. *Cancer Res* 1975; **35**: 2375-2382 [PMID: 1149042]

39 **Gahan PB**, Anker P, Stroun M. Metabolic DNA as the origin of spontaneously released DNA? *Ann N Y Acad Sci* 2008; **1137**: 7-17 [PMID: 18837918 DOI: 10.1196/annals.1448.046]

40 **Bromberg JS,** Brennan DC, Poggio E, Bunnapradist S, Langone A, Sood P, Matas AJ, Mannon RB, Mehta S, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen DJ, Zaky ZS, Hiller D, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Bloom RD. Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. *J Appl Lab Med* 2017; **2**: 309-321 [DOI: 10.1373/jalm.2016.022731]

41 **Leon SA**, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res* 1977; **37**: 646-650 [PMID: 837366]

42 **Sorenson GD**, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. *Cancer Epidemiol Biomarkers Prev* 1994; **3**: 67-71 [PMID: 8118388]

43 **Vasioukhin V**, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. *Br J Haematol* 1994; **86**: 774-779 [PMID: 7918071 DOI: 10.1111/j.1365-2141.1994.tb04828.x]

44 **Crowley E**, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol* 2013; **10**: 472-484 [PMID: 23836314 DOI: 10.1038/nrclinonc.2013.110]

45 **Cescon DW,** Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. *Nature* 2020; **1**: 276-290 [DOI: 10.1038/s43018-020-0043-5]

46 **Cohen JD**, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N. Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science* 2018; **359**: 926-930 [PMID: 29348365 DOI: 10.1126/science.aar3247]

47 **Heitzer E,** Ulz P, Geigl JB. Circulating Tumor DNA as a Liquid Biopsy for Cancer. *Clin Chem* 2015; **61(1)**: 112-123 [PMID: 25388429 DOI: 10.1373/clinchem.2014.222679]

48 **Norton ME**, Wapner RJ. Cell-free DNA Analysis for Noninvasive Examination of Trisomy. *N Engl J Med* 2015; **373**: 2582 [PMID: 26699179 DOI: 10.1056/NEJMc1509344]

49 **Stokowski R**, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ. Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies. *Prenat Diagn* 2015; **35**: 1243-1246 [PMID: 26332378 DOI: 10.1002/pd.4686]

50 **Chandrasekharan S**, Minear MA, Hung A, Allyse M. Noninvasive prenatal testing goes global. *Sci Transl Med* 2014; **6**: 231fs15 [PMID: 24718856 DOI: 10.1126/scitranslmed.3008704]

51 **Berenguer M**, Rayón JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, Carrasco D, López-Andujar R, Mir J, Berenguer J. Are posttransplantation protocol liver biopsies useful in the long term? *Liver Transpl* 2001; **7**: 790-796 [PMID: 11552213 DOI: 10.1053/jlts.2001.23794]

52 **Rockey DC**, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. *Hepatology* 2009; **49**: 1017-1044 [PMID: 19243014 DOI: 10.1002/hep.22742]

53 **Lo YM**, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. *Lancet* 1998; **351**: 1329-1330 [PMID: 9643800 DOI: 10.1016/s0140-6736(05)79055-3]

54 **Macher HC**, Suárez-Artacho G, Jiménez-Arriscado P, Álvarez-Gómez S, García-Fernández N, Guerrero JM, Molinero P, Trujillo-Arribas E, Gómez-Bravo MA, Rubio A. Evaluation of the State of Transplanted Liver Health by Monitoring of Organ-Specific Genomic Marker in Circulating DNA from Receptor. *Adv Exp Med Biol* 2016; **924**: 113-116 [PMID: 27753030 DOI: 10.1007/978-3-319-42044-8\_22]

55 **Koboldt DC**, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. *Cell* 2013; **155**: 27-38 [PMID: 24074859 DOI: 10.1016/j.cell.2013.09.006]

56 **Kumar S,** Banks TW, Cloutier S. SNP Discovery through Next-Generation Sequencing and Its Applications. *Int J Plant Genomics* 2012; **2012:** 831460 [PMID: 23227038 DOI: 10.1155/2012/831460]

57 **Snyder TM**, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. *Proc Natl Acad Sci U S A* 2011; **108**: 6229-6234 [PMID: 21444804 DOI: 10.1073/pnas.1013924108]

58 **Hidestrand M**, Tomita-Mitchell A, Hidestrand PM, Oliphant A, Goetsch M, Stamm K, Liang HL, Castleberry C, Benson DW, Stendahl G, Simpson PM, Berger S, Tweddell JS, Zangwill S, Mitchell ME. Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. *J Am Coll Cardiol* 2014; **63**: 1224-1226 [PMID: 24140666 DOI: 10.1016/j.jacc.2013.09.029]

59 **Gordon PM**, Khan A, Sajid U, Chang N, Suresh V, Dimnik L, Lamont RE, Parboosingh JS, Martin SR, Pon RT, Weatherhead J, Wegener S, Isaac D, Greenway SC. An Algorithm Measuring Donor Cell-Free DNA in Plasma of Cellular and Solid Organ Transplant Recipients That Does Not Require Donor or Recipient Genotyping. *Front Cardiovasc Med* 2016; **3**: 33 [PMID: 27713880 DOI: 10.3389/fcvm.2016.00033]

60 **Grskovic M**, Hiller DJ, Eubank LA, Sninsky JJ, Christopherson C, Collins JP, Thompson K, Song M, Wang YS, Ross D, Nelles MJ, Yee JP, Wilber JC, Crespo-Leiro MG, Scott SL, Woodward RN. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. *J Mol Diagn* 2016; **18**: 890-902 [PMID: 27727019 DOI: 10.1016/j.jmoldx.2016.07.003]

61 **Hindson CM**, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M. Absolute quantification by droplet digital PCR versus analog real-time PCR. *Nat Methods* 2013; **10**: 1003-1005 [PMID: 23995387 DOI: 10.1038/nmeth.2633]

62 **Apanius V**, Penn D, Slev PR, Ruff LR, Potts WK. The nature of selection on the major histocompatibility complex. *Crit Rev Immunol* 1997; **17**: 179-224 [PMID: 9094452 DOI: 10.1615/critrevimmunol.v17.i2.40]

63 **Yacoub R**, Nadkarni GN, Cravedi P, He JC, Delaney VB, Kent R, Chauhan KN, Coca SG, Florman SS, Heeger PS, Murphy B, Menon MC. Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. *Kidney Int* 2018; **93**: 482-490 [PMID: 28965746 DOI: 10.1016/j.kint.2017.07.016]

64 **Mills RE**, Luttig CT, Larkins CE, Beauchamp A, Tsui C, Pittard WS, Devine SE. An initial map of insertion and deletion (INDEL) variation in the human genome. *Genome Res* 2006; **16**: 1182-1190 [PMID: 16902084 DOI: 10.1101/gr.4565806]

65 **Dengu F**. Next-generation sequencing methods to detect donor-derived cell-free DNA after transplantation. *Transplant Rev (Orlando)* 2020; **34**: 100542 [PMID: 32265093 DOI: 10.1016/j.trre.2020.100542]

66 **Beck J**, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta JE, Walson P, Kollmar O, Oellerich M, Schütz E. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. *Clin Chem* 2013; **59**: 1732-1741 [PMID: 24061615 DOI: 10.1373/clinchem.2013.210328]

67 **Okino ST**, Kong M, Sarras H, Wang Y. Evaluation of bias associated with high-multiplex, target-specific pre-amplification. *Biomol Detect Quantif* 2016; **6**: 13-21 [PMID: 27077043 DOI: 10.1016/j.bdq.2015.12.001]

68 **Macher HC**, Suárez-Artacho G, Guerrero JM, Gómez-Bravo MA, Álvarez-Gómez S, Bernal-Bellido C, Dominguez-Pascual I, Rubio A. Monitoring of transplanted liver health by quantification of organ-specific genomic marker in circulating DNA from receptor. *PLoS One* 2014; **9**: e113987 [PMID: 25489845 DOI: 10.1371/journal.pone.0113987]

69 **Kanzow P**, Kollmar O, Schütz E, Oellerich M, Schmitz J, Beck J, Walson PD, Slotta JE. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. *Transplantation* 2014; **98**: e43-e45 [PMID: 25171533 DOI: 10.1097/TP.0000000000000303]

70 **Oellerich M,** Kanzow P, Beck J, Schmitz J, Kollmar O, Walson P, Schutz E. Graft-Derived Cell-Free DNA (GcfDNA) as a Sensitive Measure of Individual Graft Integrity After Liver Transplantation.: Abstract# A7. *Am J* *Transplantation* 2014; **98**: 874 [DOI: [10.1111/ajt.12896](https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.1111%2Fajt.12896)]

71 **Schütz E**, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, Oellerich M. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. *PLoS Med* 2017; **14**: e1002286 [PMID: 28441386 DOI: 10.1371/journal.pmed.1002286]

72 **Beck J**, Oellerich M, Schütz E. A Universal Droplet Digital PCR Approach for Monitoring of Graft Health After Transplantation Using a Preselected SNP Set. *Methods Mol Biol* 2018; **1768**: 335-348 [PMID: 29717452 DOI: 10.1007/978-1-4939-7778-9\_19]

73 **van der Meer AJ**, Kroeze A, Hoogendijk AJ, Soussan AA, Ellen van der Schoot C, Wuillemin WA, Voermans C, van der Poll T, Zeerleder S. Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans. *Blood Adv* 2019; **3**: 724-728 [PMID: 30814057 DOI: 10.1182/bloodadvances.2018018895]

74 **Nishimoto S**, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, Kim-Kaneyama JR, Sato F, Bando M, Yagi S, Soeki T, Hayashi T, Imoto I, Sakaue H, Shimabukuro M, Sata M. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. *Sci Adv* 2016; **2**: e1501332 [PMID: 27051864 DOI: 10.1126/sciadv.1501332]

75 **Hummel EM,** Hessas E, Müller S, Beiter T, Fisch M, Eibl A, Wolf OT, Giebel B, Platen P, Kumsta R, Moser DA. Cell-free DNA release under psychosocial and physical stress conditions. *Transl Psychiatry* 2018; **8(1)**: 236 [PMID: 30374018 DOI: 10.1038/s41398-018-0264-x]

76 **De Simone P**, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S, Sudan D, Fung J, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Witte S, Jiang H, Hexham JM, Junge G; H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. *Am J Transplant* 2012; **12**: 3008-3020 [PMID: 22882750 DOI: 10.1111/j.1600-6143.2012.04212.x]

77 **Sood S**, Haifer C, Yu L, Pavlovic J, Churilov L, Gow PJ, Jones RM, Angus PW, Visvanathan K, Testro AG. A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation. *Liver Transpl* 2017; **23**: 487-497 [PMID: 28133934 DOI: 10.1002/lt.24730]

78 **Goh SK**, Do H, Testro A, Pavlovic J, Vago A, Lokan J, Jones RM, Christophi C, Dobrovic A, Muralidharan V. The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation. *Transplant Direct* 2019; **5**: e462 [PMID: 31334336 DOI: 10.1097/TXD.0000000000000902]

79 **Goh SK**, Muralidharan V, Christophi C, Do H, Dobrovic A. Probe-Free Digital PCR Quantitative Methodology to Measure Donor-Specific Cell-Free DNA after Solid-Organ Transplantation. *Clin Chem* 2017; **63**: 742-750 [PMID: 28100495 DOI: 10.1373/clinchem.2016.264838]

80 **Ng HI**, Sun LY, Zhu ZJ. Application of graft-derived cell-free DNA in ornithine transcarbamylase deficiency patient after living donor liver transplantation: Two case reports. *Medicine (Baltimore)* 2018; **97**: e13843 [PMID: 30572553 DOI: 10.1097/MD.0000000000013843]

81 **Ng HI**, Sun LY, Zhu ZJ. Detecting Graft-Derived Cell-Free DNA Through Amplification Refractory Mutation System Polymerase Chain Reaction in Living-Donor Liver Transplantation: Report of 2 Cases. *Transplant Proc* 2019; **51**: 820-822 [PMID: 30979470 DOI: 10.1016/j.transproceed.2018.11.011]

82 **Ng HI**, Zhu X, Xuan L, Long Y, Mao Y, Shi Y, Sun L, Liang B, Scaglia F, Choy KW, Zhu Z. Analysis of fragment size distribution of cell-free DNA: A potential non-invasive marker to monitor graft damage in living-related liver transplantation for inborn errors of metabolism. *Mol Genet Metab* 2019; **127**: 45-50 [PMID: 31027872 DOI: 10.1016/j.ymgme.2019.03.004]

83 **Jiang P**, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, Wong GL, Chan SL, Mok TS, Chan HL, Lai PB, Chiu RW, Lo YM. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. *Proc Natl Acad Sci U S A* 2015; **112**: E1317-E1325 [PMID: 25646427 DOI: 10.1073/pnas.1500076112]

84 **Jiang P**, Lo YMD. The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. *Trends Genet* 2016; **32**: 360-371 [PMID: 27129983 DOI: 10.1016/j.tig.2016.03.009]

85 **von Meijenfeldt FA**, Burlage LC, Bos S, Adelmeijer J, Porte RJ, Lisman T. Elevated Plasma Levels of Cell-Free DNA During Liver Transplantation Are Associated With Activation of Coagulation. *Liver Transpl* 2018; **24**: 1716-1725 [PMID: 30168653 DOI: 10.1002/lt.25329]

86 **Goh SK**, Muralidharan V, Christophi C, Dobrovic A. Fresh Frozen Plasma Transfusion Can Confound the Analysis of Circulating Cell-Free DNA. *Clin Chem* 2018; **64**: 749-751 [PMID: 29440117 DOI: 10.1373/clinchem.2017.285684]

87 **Gielis EM**, Beirnaert C, Dendooven A, Meysman P, Laukens K, De Schrijver J, Van Laecke S, Van Biesen W, Emonds MP, De Winter BY, Bosmans JL, Del Favero J, Abramowicz D, Ledeganck KJ. Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. *PLoS One* 2018; **13**: e0208207 [PMID: 30521549 DOI: 10.1371/journal.pone.0208207]

88 **Oellerich M**, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. *Am J Transplant* 2019; **19**: 3087-3099 [PMID: 31062511 DOI: 10.1111/ajt.15416]

89 **Khush KK**, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, Ewald G, Berman P, Kanwar M, Hiller D, Yee JP, Woodward RN, Hall S, Kobashigawa J. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. *Am J Transplant* 2019; **19**: 2889-2899 [PMID: 30835940 DOI: 10.1111/ajt.15339]

90 **Richmond ME**, Zangwill SD, Kindel SJ, Deshpande SR, Schroder JN, Bichell DP, Knecht KR, Mahle WT, Wigger MA, Gaglianello NA, Pahl E, Simpson PM, Dasgupta M, North PE, Hidestrand M, Tomita-Mitchell A, Mitchell ME. Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation. *J Heart Lung Transplant* 2020; **39**: 454-463 [PMID: 31983667 DOI: 10.1016/j.healun.2019.11.015]

91 **Agbor-Enoh S**, Wang Y, Tunc I, Jang MK, Davis A, De Vlaminck I, Luikart H, Shah PD, Timofte I, Brown AW, Marishta A, Bhatti K, Gorham S, Fideli U, Wylie J, Grimm D, Goodwin N, Yang Y, Patel K, Zhu J, Iacono A, Orens JB, Nathan SD, Marboe C, Berry GJ, Quake SR, Khush K, Valantine HA. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. *EBioMedicine* 2019; **40**: 541-553 [PMID: 30692045 DOI: 10.1016/j.ebiom.2018.12.029]

92 **Meddeb R**, Pisareva E, Thierry AR. Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. *Clin Chem* 2019; **65**: 623-633 [PMID: 30792266 DOI: 10.1373/clinchem.2018.298323]

93 **Lehmann-Werman R**, Magenheim J, Moss J, Neiman D, Abraham O, Piyanzin S, Zemmour H, Fox I, Dor T, Grompe M, Landesberg G, Loza BL, Shaked A, Olthoff K, Glaser B, Shemer R, Dor Y. Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. *JCI Insight* 2018; **3**: [PMID: 29925683 DOI: 10.1172/jci.insight.120687]

94 **Moss J**, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, Samet Y, Maoz M, Druid H, Arner P, Fu KY, Kiss E, Spalding KL, Landesberg G, Zick A, Grinshpun A, Shapiro AMJ, Grompe M, Wittenberg AD, Glaser B, Shemer R, Kaplan T, Dor Y. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat Commun* 2018; **9**: 5068 [PMID: 30498206 DOI: 10.1038/s41467-018-07466-6]

95 **Cox DRA**, Wong BKL, Yang L, Yoshino O, Testro A, Muralidharan V, Dobrovic A. High Speed Centrifugation Before Frozen Storage of Plasma Is Critical for Quantitative Analysis of Mitochondrial-Derived Cell-Free DNA. *Clin Chem* 2020; **66**: 1111-1114 [PMID: 32671378 DOI: 10.1093/clinchem/hvaa127]

96 **Menon MC**, Banu K. Circulating Donor Mitochondrial DNA: Tales the Dead May Tell. *Transplantation* 2019; **103**: 2217-2218 [PMID: 30747848 DOI: 10.1097/TP.0000000000002597]

97 **Bloom RD**, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-Free DNA and Active Rejection in Kidney Allografts. *J Am Soc Nephrol* 2017; **28**: 2221-2232 [PMID: 28280140 DOI: 10.1681/ASN.2016091034]

98 **Crespo-Leiro MG**, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczyński M, Fiocchi R, Hoefer D, Colvin M, Deng MC, Leprince P, Elashoff B, Yee JP, Vanhaecke J. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. *Eur Heart J* 2016; **37**: 2591-2601 [PMID: 26746629 DOI: 10.1093/eurheartj/ehv682]

99 **Deng MC**, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa J, Johnson FL, Starling RC, Murali S, Pauly DF, Baron H, Wohlgemuth JG, Woodward RN, Klingler TM, Walther D, Lal PG, Rosenberg S, Hunt S; CARGO Investigators. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. *Am J Transplant* 2006; **6**: 150-160 [PMID: 16433769 DOI: 10.1111/j.1600-6143.2005.01175.x]

100 **Sigdel TK**, Archila FA, Constantin T, Prins SA, Liberto J, Damm I, Towfighi P, Navarro S, Kirkizlar E, Demko ZP, Ryan A, Sigurjonsson S, Sarwal RD, Hseish SC, Chan-On C, Zimmermann B, Billings PR, Moshkevich S, Sarwal MM. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. *J Clin Med* 2018; **8**: [PMID: 30583588 DOI: 10.3390/jcm8010019]

**Footnotes**

**Conflict-of-interest statement:** All authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** August 2, 2020

**First decision:** September 17, 2020

**Article in press:** October 30, 2020

**Specialty type:** Transplantation

**Country/Territory of origin:** Australia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Muro M **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Wang LL

**Figure Legends**



**Figure 1 The concept of donor-specific cell-free DNA in liver transplantation.**

**Table 1 Publications examining donor-specific cell-free DNA in liver transplantation recipients (prior to census data of July 1st, 2020)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Assay method** | **Genetic marker(s)** | **Study design**  **and sample size** | **‘‘Healthy’’ threshold** | **Diagnostic accuracy** |
| Lo *et al*[53] | 1998 | PCR and gel electrophoresis | Y chromosome | Prospective, cross-sectional  (*n* = 8) | - | - |
| Beck *et al*[66] | 2013 | ddPCR(probe-based) | SNP | Prospective, cross-sectional  (*n* = 10) and longitudinal  (*n* = 7) | 10% | - |
| Macher *et al*[68] | 2014 | qPCR(probe-based) | Y chromosome | Prospective, longitudinal  (*n* = 10) | 150 ng/mL | - |
| Macher *et al*[54] | 2016 | qPCR(probe-based) | Rhesus gene | Prospective, longitudinal  (*n* = 17) | - | - |
| Kanzow *et al*[69] | 2014 | ddPCR(probe-based) | SNP | Retrospective, longitudinal  (*n* = 1) | 10% | - |
| Oellerich *et al*[70] | 2014 | ddPCR(probe-based) | SNP | Prospective, longitudinal  (*n* = 10) | 10% | - |
| Schütz *et al*[71] | 2017 | ddPCR(probe-based) | SNP | Prospective, longitudinal  (*n* = 115) | 10% | AUC for BPAR 0.97 |
| Goh *et al*[79] | 2017 | ddPCR(probe-free) | DIP | Prospective, longitudinal  (*n* = 3) | - | - |
| Ng *et al*[80] | 2018 | NGS(targeted) | Y chromosome | Prospective, longitudinal  (*n* = 2) | 0.1 | - |
| Goh *et al*[78] | 2019 | ddPCR(probe-free) | DIP | Prospective, longitudinal  (*n* = 20) and cross-sectional  (*n* = 20) | 898 copies/mL | AUC for tBPAR 0.97 |
| Ng *et al*[81] | 2019 | qPCR(probe-free) | SNP | Prospective, longitudinal  (*n* = 2) | 0.1 | - |
| Ng *et al*[82] | 2019 | NGS(targeted)  and automated electrophoresis | Y chromosome, DNA fragments < 145 bp | Prospective, longitudinal  (*n* = 11) | 0.1, 0.6 (S/L fragments) | - |

PCR: Polymerase chain reaction; ddPCR: Droplet digital PCR; SNP: Single nucleotide polymorphism; qPCR: Quantitative PCR; DIP: Deletion insertion polymorphism; BPAR: Biopsy-proven acute rejection; tBPAR: Treated BPAR with rejection activity index > 3; NGS: Next generation sequencing; bp: Base pairs; S/L fragments: Short to long fragment ratio; AUC: Area under the receiver operating characteristic curve.